The Problem with Propofol

Demand for propofol—the ubiquitous intravenous anesthetic—has skyrocketed since the drug became key to ventilating ICU patients with COVID-19.
But hospitals have seen stressful shortages.

An investigation tracking propofol’s notoriously opaque journey from production to patient care underscores the vulnerabilities of a supply chain that relies on a few countries for production—and now faces a global crisis.
A more resilient supply—as with gasoline—is needed, says Ronald Piervincenzi of US Pharmacopeia. “They don't have ‘just in time’ delivery all along [the supply chain], they have big tanks full of gas, they sit around, they wait until the station needs it. It's built into your price.”  
Bureau of Investigative Journalism

Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top